NZ569329A - Substituted imidazole derivatives and their use as PTPase inhibitors - Google Patents

Substituted imidazole derivatives and their use as PTPase inhibitors

Info

Publication number
NZ569329A
NZ569329A NZ569329A NZ56932907A NZ569329A NZ 569329 A NZ569329 A NZ 569329A NZ 569329 A NZ569329 A NZ 569329A NZ 56932907 A NZ56932907 A NZ 56932907A NZ 569329 A NZ569329 A NZ 569329A
Authority
NZ
New Zealand
Prior art keywords
phenyl
imidazol
dichloro
compound
dioxide
Prior art date
Application number
NZ569329A
Other languages
English (en)
Inventor
Adnan M M Mjalli
Dharma R Polisetti
James C Quada
Ravindra R Yarragunta
Robert C Andrews
Rongyuan Xie
Govindan Subramanian
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of NZ569329A publication Critical patent/NZ569329A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ569329A 2006-01-30 2007-01-30 Substituted imidazole derivatives and their use as PTPase inhibitors NZ569329A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76325606P 2006-01-30 2006-01-30
PCT/US2007/002675 WO2007089857A2 (en) 2006-01-30 2007-01-30 Substituted imidazole derivatives and their use as ptpase inhibitors

Publications (1)

Publication Number Publication Date
NZ569329A true NZ569329A (en) 2011-09-30

Family

ID=38042619

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ569329A NZ569329A (en) 2006-01-30 2007-01-30 Substituted imidazole derivatives and their use as PTPase inhibitors

Country Status (13)

Country Link
US (3) US7723369B2 (enExample)
EP (1) EP1991544B1 (enExample)
JP (1) JP5180099B2 (enExample)
KR (1) KR20080094806A (enExample)
CN (1) CN101374835B (enExample)
AU (1) AU2007211319B9 (enExample)
BR (1) BRPI0707338A2 (enExample)
CA (1) CA2637024C (enExample)
EA (1) EA019385B1 (enExample)
IL (1) IL192557A (enExample)
NZ (1) NZ569329A (enExample)
WO (1) WO2007089857A2 (enExample)
ZA (1) ZA200805648B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080346A1 (en) * 2004-02-12 2005-09-01 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
EP1991544B1 (en) * 2006-01-30 2018-08-15 vTv Therapeutics LLC Substituted imidazole derivatives and their use as ptpase inhibitors
SG176628A1 (en) 2009-06-05 2012-01-30 Link Medicine Corp Aminopyrrolidinone derivatives and uses thereof
US20120135997A1 (en) 2009-07-17 2012-05-31 Shionogi & Co., Ltd. Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
JP5398076B2 (ja) * 2009-12-10 2014-01-29 四国化成工業株式会社 ２−（ブロモベンジル）−４−（ブロモフェニル）−５−メチルイミダゾール化合物
JP5398075B2 (ja) * 2010-01-13 2014-01-29 四国化成工業株式会社 ４−（ジクロロフェニル）−２−（４−フルオロベンジル）−５−メチルイミダゾール化合物
CN103298469A (zh) 2010-08-31 2013-09-11 首尔大学校产学协力财团 PPARδ激动剂的胎儿重编程的用途
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2012094580A2 (en) 2011-01-07 2012-07-12 High Point Pharmaceuticals, Llc Compounds that modulate oxidative stress
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
WO2017053706A1 (en) * 2015-09-23 2017-03-30 The General Hospital Corporation Tead transcription factor autopalmitoylation inhibitors
AU2016333963C1 (en) 2015-10-07 2021-05-27 The Salk Institute For Biological Studies PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
US11358954B2 (en) 2016-04-13 2022-06-14 Mitobridge, Inc. PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
KR102218333B1 (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
TWI888352B (zh) * 2018-06-21 2025-07-01 美商嘉來克生命科學有限責任公司 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
JP2022525186A (ja) 2019-03-15 2022-05-11 ザ ジェネラル ホスピタル コーポレイション Ｔｅａｄ転写因子新規小分子阻害剤
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
US20230265082A1 (en) * 2020-08-10 2023-08-24 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
WO2022076764A1 (en) * 2020-10-09 2022-04-14 Bristol-Myers Squibb Company Aminoimidazole fpr2 agonists
CN116348464B (zh) * 2020-10-12 2026-06-16 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
CN117658947B (zh) * 2022-09-06 2026-03-06 杭州中美华东制药有限公司 蛋白酪氨酸磷酸酶抑制作用的5-(取代芳基)-1,2,5-噻二唑啉-3-酮类化合物

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63276054A (ja) 1987-05-07 1988-11-14 Hitachi Chem Co Ltd 電子写真感光体
ATE137805T1 (de) 1989-02-14 1996-05-15 Wako Pure Chem Ind Ltd Verfahren zur erhöhung von chemilumineszenz
EP0553009B1 (fr) 1992-01-23 1997-06-04 Institut Francais Du Petrole Catalyseur d'alkylation de paraffines
US5510362A (en) 1992-03-13 1996-04-23 Merck, Sharp And Dohme Limited Imidazole, triazole and tetrazole derivatives
US5348969A (en) 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
AU5118893A (en) 1992-10-13 1994-05-09 Nippon Soda Co., Ltd. Oxazole and thiazole derivatives
JPH09502614A (ja) 1993-09-14 1997-03-18 メルク エンド カンパニー インコーポレーテッド 新規ヒト蛋白質チロシンホスファターゼをコードするｃＤＮＡ
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
ATE301457T1 (de) 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US6388076B1 (en) 1995-06-19 2002-05-14 Ontogen Corporation Protein tyrosine phosphatase-inhibiting compounds
US5753687A (en) 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
JP3849157B2 (ja) 1995-08-01 2006-11-22 東ソー株式会社 ２−イミダゾリン類の製造法
US6238902B1 (en) 1996-03-22 2001-05-29 Genentech, Inc. Protein tyrosine phosphatases
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
AU740425B2 (en) * 1996-12-16 2001-11-01 Ontogen Corporation Modulators of proteins with phosphotyrosine recognition units
US5840721A (en) 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
GB9715816D0 (en) 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
FR2767527B1 (fr) 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
AU749132B2 (en) 1997-08-28 2002-06-20 Biovitrum Ab Inhibitors of protein tyrosine phosphatase
US6169087B1 (en) 1997-09-23 2001-01-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US5972986A (en) 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US20020002199A1 (en) 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6699896B1 (en) 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
JP2002516305A (ja) 1998-05-12 2002-06-04 アメリカン・ホーム・プロダクツ・コーポレイション インスリン抵抗性および高血糖症の治療に有用な２，３，５−置換ビフェニル
US20030194745A1 (en) 1998-06-26 2003-10-16 Mcdowell Robert S. Cysteine mutants and methods for detecting ligand binding to biological molecules
WO2000006712A2 (en) 1998-07-24 2000-02-10 Merck Frosst Canada & Co. Protein tyrosine phosphatase-1b (ptp-1b) deficient mice and uses thereof
US6174874B1 (en) 1998-09-21 2001-01-16 Merck Frosst Canada & Co. Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)
JP2002532515A (ja) 1998-12-11 2002-10-02 マクギル ユニバーシティー 蛋白質チロシンホスファターゼｔｃ−ｐｔｐの治療的および診断的利用
JP4221129B2 (ja) 1999-02-15 2009-02-12 富士フイルム株式会社 含窒素ヘテロ環化合物、有機発光素子材料、有機発光素子
AU4738600A (en) 1999-05-14 2000-12-05 Merck Frosst Canada & Co. Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1b (ptp-1b)
ATE257827T1 (de) 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
DE60023920T2 (de) 1999-08-27 2006-07-20 Sugen, Inc., South San Francisco Phosphatmimetika und Verfahren zur Behandlung mit Phosphataseinhibitoren HIBITOREN
US6410556B1 (en) 1999-09-10 2002-06-25 Novo Nordisk A/S Modulators of protein tyrosine phosphateses (PTPases)
EP1227084B1 (en) 1999-10-28 2005-12-14 Trine Pharmaceuticals, Inc. Drug discharge pump inhibitors
US6624182B1 (en) 1999-11-25 2003-09-23 Ciba Specialty Chemicals Corporation Hydroxyphenylvinylthiazoles
JP2003518128A (ja) 1999-12-22 2003-06-03 メルク フロスト カナダ アンド カンパニー タンパク質チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）のインヒビターとなる芳香族ホスホネート
WO2001046206A1 (en) 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
CA2394834A1 (en) 1999-12-22 2001-06-28 Merck Frosst Canada Inc. Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
JP2003518129A (ja) 1999-12-22 2003-06-03 メルク フロスト カナダ アンド カンパニー タンパク質チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）のインヒビターとなるホスホン酸誘導体
US6777433B2 (en) 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
AU2001232833A1 (en) 2000-01-18 2001-07-31 Human Genome Sciences, Inc. Human protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
WO2001061031A2 (en) 2000-02-14 2001-08-23 Ceptyr, Inc. Improved assay for protein tyrosine phosphatases
US6498151B2 (en) 2000-03-22 2002-12-24 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
US6627647B1 (en) 2000-03-23 2003-09-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
US6911468B2 (en) 2000-05-22 2005-06-28 Takeda Chemical Industries, Ltd. Tyrosine phosphatase inhibitors
WO2002004412A2 (en) 2000-07-06 2002-01-17 Array Biopharma Inc. Tyrosine derivatives as phosphatase inhibitors
US20020099073A1 (en) 2000-07-07 2002-07-25 Andersen Henrik Sune Modulators of protein tyrosine phosphatases (PTPases)
US6613903B2 (en) 2000-07-07 2003-09-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US20020169157A1 (en) 2000-08-29 2002-11-14 Gang Liu Selective protein tyrosine phosphatatase inhibitors
US6627767B2 (en) 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
US20020035137A1 (en) 2000-08-29 2002-03-21 Gang Liu Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors
US6472545B2 (en) 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
US6972340B2 (en) 2000-08-29 2005-12-06 Abbott Laboratories Selective protein tyrosine phosphatatase inhibitors
GB0022079D0 (en) 2000-09-08 2000-10-25 Inst Of Molecul & Cell Biology Novel protein tyrosine phosphatase inhibitor
JP2002114768A (ja) 2000-10-11 2002-04-16 Japan Tobacco Inc ２−（２，５−ジハロゲン−３，４−ジヒドロキシフェニル）アゾール化合物及びそれを含有してなる医薬組成物
US20030108883A1 (en) 2001-02-13 2003-06-12 Rondinone Cristina M. Methods for identifying compounds that inhibit or reduce PTP1B expression
US20030120073A1 (en) 2001-04-25 2003-06-26 Seto Christopher T. Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
JP2002322054A (ja) 2001-04-26 2002-11-08 Dai Ichi Seiyaku Co Ltd 薬剤排出ポンプ阻害薬
WO2002102813A1 (en) 2001-06-20 2002-12-27 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids for treatment of diabetes
US20030064979A1 (en) 2001-06-29 2003-04-03 Hansen Thomas Kruse Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48
US20030170660A1 (en) 2001-07-11 2003-09-11 Sondergaard Helle Bach P387L variant in protein tyrosine phosphatase-1B is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro
CA2463441A1 (en) 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
EP1438044A1 (en) 2001-10-19 2004-07-21 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
EP1438310B1 (en) 2001-10-19 2006-12-20 TransTech Pharma Inc. Beta-carbolin derivatives as ptp-inhibitors
WO2003048140A1 (en) 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
JP2003231679A (ja) 2001-12-03 2003-08-19 Japan Tobacco Inc アゾール化合物及びその医薬用途
US6642381B2 (en) 2001-12-27 2003-11-04 Hoffman-La Roche Inc. Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
US20030180827A1 (en) 2002-01-04 2003-09-25 Aventis Pharma Deutschland Gmbh. Highly sensitive and continuous protein tyrosine phosphatase test using 6,8-difluoro-4-methylumbelliferyl phosphate
US20030215899A1 (en) 2002-02-13 2003-11-20 Ceptyr, Inc. Reversible oxidation of protein tyrosine phosphatases
US6784205B2 (en) 2002-03-01 2004-08-31 Sunesis Pharmaceuticals, Inc. Compounds that modulate the activity of PTP-1B and TC-PTP
EP1482931B1 (en) 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
ATE534637T1 (de) 2002-04-03 2011-12-15 Novartis Ag 5-substituierte 1,1-dioxo- 1,2,5 thiazolidin-3- onderivate als ptpase 1b hemmer
MXPA04009961A (es) 2002-04-12 2004-12-13 Pfizer Compuestos de imidazol como agentes anti-inflamatorios y analgesicos.
JP2003313172A (ja) 2002-04-23 2003-11-06 Tosoh Corp Ｎ−置換イミダゾール化合物の製造方法
JP4529342B2 (ja) 2002-04-23 2010-08-25 東ソー株式会社 環状アミジニウム有機酸塩の製造方法
US20040009956A1 (en) 2002-04-29 2004-01-15 Dehua Pei Inhibition of protein tyrosine phosphatases and SH2 domains by a neutral phosphotyrosine mimetic
US20040121353A1 (en) 2002-05-23 2004-06-24 Ceptyr, Inc. Modulation of TCPTP signal transduction by RNA interference
US6849761B2 (en) 2002-09-05 2005-02-01 Wyeth Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia
EP1402888A1 (en) 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
AU2003300447B2 (en) 2002-12-30 2009-09-03 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US20040186151A1 (en) 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
AU2004210711B2 (en) 2003-02-12 2010-07-08 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
US20040167188A1 (en) 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
HK1078086A1 (en) 2003-04-09 2006-03-03 日本烟草产业株式会社 Heteroaromatic pentacyclic compound and medicinal use thereof
WO2005035551A2 (en) * 2003-10-08 2005-04-21 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
WO2005080346A1 (en) * 2004-02-12 2005-09-01 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
RU2008127253A (ru) * 2005-12-08 2010-01-20 Новартис АГ (CH) 1,1,3-триоксо-1,2,5-тиадиазолидины и их применение в качестве ингибиторов птфаз
EP1963294B1 (en) * 2005-12-08 2012-10-10 Novartis AG 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (ptpase)
EP1991544B1 (en) * 2006-01-30 2018-08-15 vTv Therapeutics LLC Substituted imidazole derivatives and their use as ptpase inhibitors

Also Published As

Publication number Publication date
EA200870218A1 (ru) 2009-02-27
BRPI0707338A2 (pt) 2011-05-03
ZA200805648B (en) 2009-09-30
IL192557A (en) 2013-09-30
AU2007211319B9 (en) 2012-05-31
JP2009525340A (ja) 2009-07-09
US7723369B2 (en) 2010-05-25
IL192557A0 (en) 2009-02-11
US20120196906A1 (en) 2012-08-02
AU2007211319A1 (en) 2007-08-09
JP5180099B2 (ja) 2013-04-10
WO2007089857A3 (en) 2008-06-26
US8404731B2 (en) 2013-03-26
EA019385B1 (ru) 2014-03-31
HK1127342A1 (en) 2009-09-25
EP1991544B1 (en) 2018-08-15
CN101374835A (zh) 2009-02-25
KR20080094806A (ko) 2008-10-24
US20070191385A1 (en) 2007-08-16
US20100113331A1 (en) 2010-05-06
CA2637024C (en) 2013-05-14
CA2637024A1 (en) 2007-08-09
WO2007089857A2 (en) 2007-08-09
CN101374835B (zh) 2012-04-25
AU2007211319B2 (en) 2012-01-19
EP1991544A2 (en) 2008-11-19

Similar Documents

Publication Publication Date Title
AU2007211319B9 (en) Substituted imidazole derivatives and their use as PTPase inhibitors
AU2014209107B2 (en) Metalloenzyme inhibitor compounds
AU2006325754B2 (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors
US5463071A (en) 5-membered heterocyclic compounds, processes for preparing them and pharmaceutical compositions containing these compounds
CA3006469C (en) Metalloenzyme inhibitor compounds
AU2023212015B2 (en) Pyrrolidine compounds
NO303119B1 (no) 2-substituerte sakkarinderivater med proteolytisk enzyminhiberende aktivitet, farmas÷ytisk preparat inneholdende disse derivatene, samt anvendelse derav
JPH072851A (ja) ５員複素環化合物、それらの調製方法及びこれらの化合物を含む医薬組成物
CZ292942B6 (cs) Derivát (N-hydroxykarbamoyl)-1-(4-fenoxy)benzensulfonylu
KR20100027188A (ko) 피리다지논 유도체
EP2811997A1 (en) Substituted prolines / piperidines as orexin receptor antagonists
KR20100098657A (ko) 이미다졸카르보닐 화합물
JPH04507095A (ja) 蛋白分解酵素阻害剤として有用なサッカリン誘導体及びその製造
IL213828A (en) Derivatives of pyridazine, use, drugs and processes for their preparation
KR20080039992A (ko) 1-아실디히드로피라졸 유도체
HUT76484A (en) Novel tetrasubstituted imidazole derivatives, method for preparing same, and pharmaceutical compositions containing same
KR20040011519A (ko) 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물
CN101208328B (zh) 包含饱和连接基团的杂芳基取代的酰胺以及它们作为药物的用途
CN113754635A (zh) 稠环类化合物及其制备方法和用途
US6908940B2 (en) Imidazole compounds and their use as adenosine deaminase inhibitors
JPH08512037A (ja) 置換されたアリールチオアルキルチオピリジン
HK1127342B (en) Substituted imidazole derivatives and there use as ptpase inhibitors
MX2008007313A (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 JAN 2017 BY CPA GLOBAL

Effective date: 20131219

ASS Change of ownership

Owner name: TRANSTECH PHARMA, LLC, US

Effective date: 20140109

ASS Change of ownership

Owner name: VTV THERAPEUTICS LLC, US

Effective date: 20151022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2018 BY CPA GLOBAL

Effective date: 20161217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2019 BY CPA GLOBAL

Effective date: 20171214

LAPS Patent lapsed